The Chronic Cough industry trends have evolved rapidly over the past 18 months, driven by innovation and shifting healthcare priorities. Strategic partnerships between pharmaceutical firms and digital health platforms have surged, with companies like Innovair and TeleCure collaborating to integrate AI-powered symptom tracking into treatment protocols. Notably, the acquisition of BioResp by GlaxoSmithKline in 2023 strengthened its portfolio in neuromodulation therapies, marking a pivotal shift toward non-pharmacological solutions. Meanwhile, product launches such as PulmoTech’s FDA-cleared inhaled anti-inflammatory, AirCalm, underscored advancements in targeted drug delivery. Regulatory bodies, including the EMA, have also prioritized guideline updates to streamline approvals for combination therapies, easing market entry for biotech startups. On the consumer side, a growing preference for personalized medicine and telehealth consultations has reshaped demand, pushing companies to invest in patient-centric digital tools. Lastly, a $120M funding round led by HealthVest Capital fueled expansion in Asia-Pacific markets, where chronic cough prevalence linked to air pollution is rising. These dynamics signal a forward-looking industry poised for disruptive growth.
